6 Recruiting Hematological Malignancies Phase 2 Clinical Trials
Active phase 2 studies for hematological malignancies enrolling across the USA. Verify eligibility and contact site coordinators.
All Hematological Malignancies studiesPhase 2 Studies for Hematological Malignancies
🔵 Active, Not Recruiting Phase2
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase2
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
📍 Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
📍 Research Site — New York, New York
View Study & Checklist ➔ 🟢 Recruiting Phase2
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
📍 University of Nebraska Medical Center — Omaha, Nebraska
View Study & Checklist ➔